HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus.

Abstract
CD40/CD40L signaling promotes both B cell and CTL responses in vivo, the latter being beneficial in tumor models. Because CTL may also limit autoreactive B cell expansion in lupus, we asked whether an agonist CD40 mAb would exacerbate lupus due to B cell stimulation or would improve lupus due to CTL promotion. These studies used an induced model of lupus, the parent-into-F1 model in which transfer of DBA/2 splenocytes into B6D2F1 mice induces chronic lupus-like graft-vs-host disease (GVHD). Although agonist CD40 mAb treatment of DBA-->F1 mice initially exacerbated B cell expansion, it also strongly promoted donor CD8 T cell engraftment and cytolytic activity such that by 10 days host B cells were eliminated consistent with an accelerated acute GVHD. CD40 stimulation bypassed the requirement for CD4 T cell help for CD8 CTL possibly by licensing dendritic cells (DC) as shown by the following: 1) greater initial activation of donor CD8 T cells, but not CD4 T cells; 2) earlier activation of host DC; 3) host DC expansion that was CD8 dependent and CD4 independent; and 4) induction of acute GVHD using CD4-depleted purified DBA CD8+ T cells. A single dose of CD40 mAb improved lupus-like renal disease at 12 wk, but may not suffice for longer periods consistent with a need for continuing CD8 CTL surveillance. These results demonstrate that in the setting of lupus-like CD4 T cell-driven B cell hyperactivity, CTL promotion is both feasible and beneficial and the CTL-promoting properties of CD40 stimulation outweigh the B cell-stimulatory properties.
AuthorsRoman Puliaev, Irina Puliaeva, Lisbeth A Welniak, Abigail E Ryan, Mark Haas, William J Murphy, Charles S Via
JournalJournal of immunology (Baltimore, Md. : 1950) (J Immunol) Vol. 181 Issue 1 Pg. 47-61 (Jul 01 2008) ISSN: 0022-1767 [Print] United States
PMID18566369 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Antibodies, Monoclonal
  • CD40 Antigens
Topics
  • Animals
  • Antibodies, Monoclonal (immunology, therapeutic use)
  • B-Lymphocytes (immunology)
  • CD4-Positive T-Lymphocytes (immunology)
  • CD40 Antigens (agonists, immunology)
  • Cells, Cultured
  • Cytotoxicity, Immunologic (immunology)
  • Dendritic Cells (immunology)
  • Disease Models, Animal
  • Graft vs Host Disease (drug therapy, immunology)
  • Lupus Erythematosus, Systemic (immunology)
  • Lymphocyte Activation (immunology)
  • Male
  • Mice
  • Phenotype
  • T-Lymphocytes, Cytotoxic (immunology)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: